Aminosteroidal non-depolarizing neuromuscular blocking agent (None)

Aminosteroidal non-depolarizing neuromuscular blocking agents are a subclass of synthetic muscle relaxants used in anesthesia to induce skeletal muscle paralysis, most commonly during surgical procedures or mechanical ventilation. These drugs are characterized by an amino-substituted steroid structure and act by competitively antagonizing the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction, thereby preventing acetylcholine from initiating muscle contraction[1][3][4]. They do not cause depolarization and, unlike some other muscle relaxants, typically do not trigger histamine release, reducing the risk of allergic-type cardiovascular side effects[2]. The class includes widely used agents such as vecuronium, pancuronium, and rocuronium. Clearance is primarily renal or hepatic, and safety considerations include the risk of prolonged paralysis if organ function is impaired[2][6]. Note: "Aminosteroidal nondepolarizing NMBAs" is not a single molecular target, receptor, or protein—it is a drug class. The true molecular target of these drugs is the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction[3][4][5]. For structured target information (e.g., for use in a database of drug targets), you should map the class to "Nicotinic acetylcholine receptor, muscle type" as the canonical target, and then separately classify the drugs under the class "aminosteroidal non-depolarizing NMBAs."[3][4][5] The current target name in the query is incorrect as a molecular target.

Other names

aminosteroidal nondepolarizing NMBAaminosteroid NMBAaminosteroidal muscle relaxantaminosteroidal neuromuscular blocker

Competitive antagonism of the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction[1][3][4]